Neoadjuvant Intra-arterial Cytoreductive Chemotherapy for Lacrimal Gland Adenoid Cystic Carcinoma
Adenoid cystic carcinoma (ACC) is the most common lacrimal gland malignancy. Despite poor prognosis, the advent of neoadjuvant intra-arterial cytoreductive chemotherapy (IACC) can improve survival. We report the first case of lacrimal gland ACC from the Indian subcontinent managed with IACC. A 45-ye...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2024-12-01
|
| Series: | TNOA Journal of Ophthalmic Science and Research |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/tjosr.tjosr_96_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Adenoid cystic carcinoma (ACC) is the most common lacrimal gland malignancy. Despite poor prognosis, the advent of neoadjuvant intra-arterial cytoreductive chemotherapy (IACC) can improve survival. We report the first case of lacrimal gland ACC from the Indian subcontinent managed with IACC. A 45-year-old gentleman presented with painful proptosis with restricted ocular movements in right eye for 6 months. Imaging showed an ill-defined heterogeneous mass involving the right lacrimal gland with calcification and adjacent bony erosion. Incision biopsy confirmed the diagnosis of lacrimal gland ACC. He received 2 cycles of neoadjuvant intra-arterial cisplatin before tumour excision followed by adjuvant chemoradiation. He had no recurrence at 6 years of follow-up. IACC helps to reduce tumour size, thereby enabling complete tumour excision and globe salvage. IACC is a treatment option worth considering for patients presenting with a large lacrimal gland ACC. |
|---|---|
| ISSN: | 2589-4528 2589-4536 |